International Journal of Biological Markers最新文献

{"title":"Serum epithelial membrane protein 1 serves as a feasible biomarker in extrahepatic cholangiocarcinoma.","authors":"Xiang Li,&nbsp;Lang Yan,&nbsp;Hao Xue","doi":"10.1177/17246008211035142","DOIUrl":"https://doi.org/10.1177/17246008211035142","url":null,"abstract":"<p><strong>Background: </strong>Extrahepatic cholangiocarcinoma is a malignancy that originates from bile duct epithelium with an unfavorable prognosis. Epithelial membrane protein 1 was first discovered in 1995, functioning as an oncogene or anti-tumor gene in various cancers. However, the clinical role of epithelial membrane protein 1 extrahepatic cholangiocarcinoma remained unclear.</p><p><strong>Methods: </strong>Differentially expressed genes were identified using Gene Ontology and the Kyoto Encyclopedia and Genomes pathway analysis. Out of 183 extrahepatic cholangiocarcinoma patients and 61 healthy controls, the expression level of epithelial membrane protein 1 was detected and compared using reverse transcription-quantitative polymerase chain reaction analysis and western blot assay. Meanwhile, the diagnosis and prognosis of EMP1 in ECCA were measured by receiver operating characteristic and Kaplan-Meier analysis. Finally, the relationship between epithelial membrane protein 1 expression and clinicopathological indexes were compared to further verify the clinical role of epithelial membrane protein 1 in extrahepatic cholangiocarcinoma.</p><p><strong>Results: </strong>After analyzing data from GSE76297, GSE89749, and GSE26566GO, we found 1554 down-regulated and 1065 up-regulated genes. Through Gene Ontology and Kyoto Encyclopedia and Genomes analysis, extracellular matrix organization, extracellular structure organization, cholesterol metabolism, interleukin-17 signaling pathway, and vitamin digestion and absorption were significantly enriched and involved in targeted differentially expresses genes. Epithelial membrane protein 1 messenger ribonucleic acid was notably decreased in serum samples from extrahepatic cholangiocarcinoma patients, compared with that in healthy controls. Receiver operating characteristic analysis revealed that the area under the curve of epithelial membrane protein 1 messenger ribonucleic acid for the diagnosis of extrahepatic cholangiocarcinoma was 0.9281 (95% CI = 0.8967-0.9595). Moreover, the correlation analysis presented that epithelial membrane protein 1 expression was negatively correlated with lymph node metastasis, tumour node metastasis stage, cancer antigen 19-9 level, and carcinoembryonic antigen level.</p><p><strong>Conclusion: </strong>Aberrant expression of epithelial membrane protein 1 contributed to distinguishing extrahepatic cholangiocarcinoma patients and healthy controls, and a low expression level of epithelial membrane protein 1 indicated an unfavorable prognosis. Hence, epithelial membrane protein 1 was a feasible and credible biomarker for extrahepatic cholangiocarcinoma diagnosis and prognosis, with high accuracy, sensitivity, and specificity.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"36 3","pages":"33-39"},"PeriodicalIF":2.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39454260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TMPRSS4 overexpression promotes the metastasis of colorectal cancer and predicts poor prognosis of stage III-IV colorectal cancer.","authors":"Xue-Feng Zhao,&nbsp;Yu-Shen Yang,&nbsp;Da-Zhi Gao,&nbsp;Young Kyu Park","doi":"10.1177/17246008211046368","DOIUrl":"https://doi.org/10.1177/17246008211046368","url":null,"abstract":"<p><strong>Purpose: </strong>To study in detail the expression pattern and prognostic significance of TMPRSS4 in colorectal cancer.</p><p><strong>Methods: </strong>The expression of TMPRSS4 protein was determined using Western blot in the colorectal cancer tissues and normal tissues. Immunohistochemistry was used to detect the TMPRSS4 expression in colorectal cancer tissues, and the clinicopathologic characteristics and prognostic significance were analyzed.</p><p><strong>Results: </strong>TMPRSS4 overexpression was associated with tumor budding, lymphovascular invasion, perineural invasion, cancerous emboli, infiltration depth, lymph node metastasis, distant metastasis, and tumor node metastasis stage (<i>P</i> < 0.05 for all). Interestingly, TMPRSS4 expression in the tumor budding, tumor emboli, lymph node, and liver metastatic tumor samples was higher than in the paired primary tumors. In contrast, TMPRSS4 overexpression is inversely correlated with both the overall survival and the disease-free survival of the patients with colorectal cancer (<i>P</i> < 0.05 for both). Also, we found that TMPRSS4 is only of significance in predicting the prognosis of stage III and IV colorectal cancer, not stage I and II.</p><p><strong>Conclusions: </strong>TMPRSS4 was shown to be involved in the whole process of metastasis from tumor budding to lymph node and/or distant metastasis in colorectal cancer and predicted the unfavorable prognosis of stage III-IV, indicating that it is a novel target for the precise treatment of colorectal cancer with lymph node or distant organ metastasis.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"36 3","pages":"23-32"},"PeriodicalIF":2.0,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39475990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and prognostic value of the <i>KRAS</i> mutation in Chinese colorectal cancer patients.","authors":"Ye Yuan,&nbsp;Yingting Liu,&nbsp;Ye Wu,&nbsp;Junling Zhang,&nbsp;Chunti Shen,&nbsp;Feng Zhang,&nbsp;Changping Wu,&nbsp;Wenwei Hu","doi":"10.1177/17246008211017152","DOIUrl":"https://doi.org/10.1177/17246008211017152","url":null,"abstract":"<p><strong>Background: </strong>The <i>KRAS</i> mutations are high-frequency somatic mutations found in colorectal cancer patients from Western and Asian countries however, with the exception of exon 2 of <i>KRAS</i>, other prevalence and prognostic values have not been adequately assessed in Asian patients. The aim of this study was to determine the mutation frequencies of whole exon mutations of <i>KRAS</i> in Chinese colorectal cancer patients and to investigate their impact on prognosis.</p><p><strong>Methods: </strong>A total of 7189 tumor tissue samples (iCohort) were subjected to next-generation sequencing for detection of <i>KRAS</i> mutations. All pathologic or likely pathologic mutations of <i>KRAS</i> were considered. In addition, clinical features and prognostic dates were collected from 145 patients at The Third Affiliated Hospital of Soochow University, China (sCohort) and used droplet digital™ polymerase chain reaction to detect <i>KRAS</i> mutations.</p><p><strong>Results: </strong>In the iCohort, 2706 patients (37.6%) were confirmed harboring <i>KRAS</i> mutations. The most frequent of these mutations were <i>G12D</i> (32.19%), <i>G12V</i> (17.96%), and <i>G13D</i> (17.59%). In the sCohort, 51 colorectal cancer patients (35.17%) had <i>KRAS</i> mutations, among which <i>KRAS G12D</i> (64.71%), <i>G13D</i> (29.41%), and <i>G14D</i> (3.92%) were high-frequency. The <i>KRAS</i> mutations were associated with shorter median overall survival than wild-type tumors (69 vs. 55 months; HR 1.80; 95% Cl 1.22, 2.64; <i>P</i>=0.0003). In the Cox multivariate analysis, age (HR 1.562; 95% Cl 1.10, 2.22; <i>P</i>=0.013), tumor differentiation (HR 0.417; 95% Cl 0.19, 0.90; <i>P</i>=0.026), and <i>KRAS</i> mutation (HR 1.897; 95% Cl 0.19, 0.90; <i>P</i>=0.001) remained independent predictors of shorter overall survival. Among the common <i>KRAS</i> mutations, <i>G12D</i> was significantly associated with shorter overall survival (HR 2.17; 95% Cl 1.31, 3.58; <i>P</i> < 0.0001) compared with <i>KRAS</i> wild-type patients.</p><p><strong>Conclusions: </strong>Our findings indicate that KRAS genes are frequently mutated, and over 30% harbored the <i>KRAS G12D</i> mutation subtype. We found that the <i>KRAS G12D</i> mutation is associated with inferior survival and is a biomarker of poor prognosis in Chinese patients. Our data emphasize the importance of molecular features in colorectal cancer patients, which could potentially be improved by <i>G12D</i>-specific related inhibitors.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"36 2","pages":"33-39"},"PeriodicalIF":2.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/17246008211017152","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39039833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic significance of microRNA-221 in hepatocellular carcinoma: An updated meta-analysis.","authors":"Wenfeng Liu,&nbsp;Keshu Hu,&nbsp;Feng Zhang,&nbsp;Shenxin Lu,&nbsp;Rongxin Chen,&nbsp;Zhenggang Ren,&nbsp;Xin Yin","doi":"10.1177/17246008211032689","DOIUrl":"https://doi.org/10.1177/17246008211032689","url":null,"abstract":"<p><strong>Background: </strong>Recently, microRNA-221 has been found to be abnormally expressed in hepatocellular carcinoma; however, its clinical value has not been summarised. This meta-analysis aimed to assess the prognostic significance of miR-221 in hepatocellular carcinoma.</p><p><strong>Material and methods: </strong>PubMed, Science Direct, Web of Science, Scopus, Ovid MEDLINE, EMbase, Google Scholar, the Cochrane Library, CNKI, CBM, VIP and Wanfang databases were searched for eligible articles. The endpoints included overall survival, progression-free survival, recurrence-free survival, metastasis-free survival, disease-free survival. Hazard ratios with 95% confidence intervals were used to explore the relationship between miR-221 expression and clinical survival results of liver cancer patients. Subgroup analysis and sensitivity analysis were performed. Begg's test and Egger's test were conducted to evaluate publication bias.</p><p><strong>Results: </strong>A total of nine studies including 607 patients were recruited for this meta-analysis. The pooled hazard ratios displayed that high miR-221 expression was remarkably associated with poorer overall survival (hazard ratio = 1.91, 95% confidence interval: 1.53-2.38, <i>p</i> ＜ 0.01) and unfavourable progression-free survival/recurrence-free survival/metastasis-free survival/disease-free survival (hazard ratio = 2.02, 95% confidence interval: 1.58-2.57, <i>p</i> ＜ 0.01). The results of Begg's test and Egger's test did not exhibit obvious publication bias.</p><p><strong>Conclusions: </strong>High expression of miR-221 can predict poor outcome of hepatocellular carcinoma. miR-221 can be used as a promising prognostic biomarker of hepatocellular carcinoma.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"36 2","pages":"17246008211032689"},"PeriodicalIF":2.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39297429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of serum bilirubin in colorectal cancer patients with surgical resection.","authors":"Zhangjun Jia,&nbsp;Zeyu Zhu,&nbsp;Ying Wang,&nbsp;Jing Ding,&nbsp;Zhenzhong Lin,&nbsp;Yanyan Zhang,&nbsp;Zhipeng Li","doi":"10.1177/17246008211036128","DOIUrl":"https://doi.org/10.1177/17246008211036128","url":null,"abstract":"<p><strong>Purpose: </strong>Serum bilirubin plays an important role in antioxidant and anticancer processes. The inverse association between serum bilirubin and cancer risk have been widely reported in multiple cancers. The aim of this retrospective study was to investigate the prognostic impact of serum bilirubin in colorectal cancer patients undergoing surgical resection.</p><p><strong>Methods: </strong>The value of serum bilirubin including total bilirubin, direct bilirubin, and indirect bilirubin were tested at pre-operatively in 330 colorectal cancer patients. The optimal cut-off values for these three biomarkers were determined by X-tile program. The relationship between serum bilirubin and outcomes were examined using Kaplan-Meier curves log-rank test, univariate and multivariate cox regression. Moreover, a number of risk factors were used to form a nomogram for evaluating risk of survival.</p><p><strong>Results: </strong>The optimal cut-off points of serum total bilirubin, direct bilirubin, and indirect bilirubin were 19.5 μmol/L, 5.0 μmol/L and 8.1 μmol/L, respectively. Elevated total bilirubin and direct bilirubin were significantly associated with overall survival in surgical colorectal cancer patients. Additionally, predictive nomogram including total bilirubin and direct bilirubin for overall survival was established for predicting overall survival in surgical colorectal cancer patients.</p><p><strong>Conclusions: </strong>These findings indicated that preoperative elevated total bilirubin and direct bilirubin could be considered as independent prognostic biomarkers for poor overall survival of colorectal cancer patients.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"36 2","pages":"17246008211036128"},"PeriodicalIF":2.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39297434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five <i>MDM4</i> gene polymorphisms on cancer risk: An updated systematic review and meta-analysis.","authors":"Yaxuan Wang,&nbsp;Zhan Yang,&nbsp;Xueliang Chang,&nbsp;Jingdong Li,&nbsp;Zhenwei Han","doi":"10.1177/17246008211033874","DOIUrl":"https://doi.org/10.1177/17246008211033874","url":null,"abstract":"<p><strong>Purpose: </strong>The study aims to provide a comprehensive account of the association of five <i>MDM4</i> gene polymorphisms (rs1380576, rs1563828, rs10900598, rs11801299, and rs4245739) with susceptibility to cancer.</p><p><strong>Methods: </strong>A literature search for eligible candidate gene studies published before 27 February 2021 was conducted in PubMed, Medline and Web of Science. The following combinations of main keywords were used: (MDM4 OR MDMX OR HDMX OR mouse double minute 4 homolog) AND (polymorphism OR mutation OR variation OR SNP OR genotype) AND (cancer OR tumor OR neoplasm OR malignancy OR carcinoma OR adenocarcinoma). Potential sources of heterogeneity were sought out via meta-regression, subgroup and sensitivity analysis.</p><p><strong>Results: </strong>Overall, a total of 15 articles with 21,365 cases and 29,280 controls for five polymorphisms of the <i>MDM4</i> gene were enrolled. In the stratified analysis of rs1380576, we found that Asians might have less susceptibility to cancer. We found that rs4245739 was correlated with a decreased risk of cancer for Asians and breast cancer susceptibility. However, for other polymorphisms, the results showed no significant association with cancer risk.</p><p><strong>Conclusion: </strong><i>MDM4</i> rs1380576 polymorphism is negatively associated with the risk of cancer in the Asian population. <i>MDM4</i> rs4245739 polymorphism is inversely associated with cancer risk for Asians and breast cancer susceptibility.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"36 2","pages":"17246008211033874"},"PeriodicalIF":2.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/17246008211033874","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39275094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of EPclin on adjuvant therapeutic decision making and comparison of EPclin to the PREDICT tool.","authors":"Héloïse Bourien,&nbsp;Véronique Quillien,&nbsp;Florence Godey,&nbsp;Christophe Perrin,&nbsp;Fanny Le Du,&nbsp;Sophie Guillermet,&nbsp;Jérôme Blanchot,&nbsp;Vincent Lavoué,&nbsp;Boris Campillo-Gimenez,&nbsp;Angélique Brunot,&nbsp;Laurence Crouzet,&nbsp;Thibault De la Motte Rouge,&nbsp;Véronique Diéras,&nbsp;Claudia Lefeuvre-Plesse","doi":"10.1177/17246008211012424","DOIUrl":"https://doi.org/10.1177/17246008211012424","url":null,"abstract":"Purpose: Genomic signatures, such as EndoPredict®, may help clinicians to decide which adjuvant treatment is the most appropriate. Methods: We propose the EndoPredict® assay for unclear cases of adjuvant treatment in patients treated in our comprehensive cancer center. We prospectively and retrospectively report the decision of adjuvant treatment before and after the EndoPredict® assay, respectively, compared to the PREDICT’s tool scores. Results: From November 2016 to March 2019, 159 breast cancer tumors were analyzed and presented before and after the EndoPredict® assay. Before the EndoPredict® results, clinicians recommended chemotherapy for 57 patients (57/159, 36%). A total of 108 patients (108/159, 68%) were classified as EPclin high-risk score. There was only a slight agreement between clinicians’ decisions and EPclin risk score. The EPclin score led to 37% changes in treatment (59/159); chemotherapy was favored in 80% of cases (47/59). The PREDICT tool recommended chemotherapy for 16 high-risk patients (16/159, 10%). Conclusion: Although genomic tests were developed in order to de-escalate adjuvant treatment, in our comprehensive cancer center the use of the EndoPredict® assay led to an increase in prescribed chemotherapy.","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"36 2","pages":"57-63"},"PeriodicalIF":2.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/17246008211012424","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39011095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical value of serum and exhaled breath condensate inflammatory factor IL-11 levels in non-small cell lung cancer: Clinical value of IL-11 in non-small cell lung cancer.","authors":"Jinnan Wu,&nbsp;Jinliang Chen,&nbsp;Xuedong Lv,&nbsp;Qichang Yang,&nbsp;Sumei Yao,&nbsp;Dongmei Zhang,&nbsp;Jianrong Chen","doi":"10.1177/17246008211023515","DOIUrl":"https://doi.org/10.1177/17246008211023515","url":null,"abstract":"<p><strong>Objective: </strong>Our study aimed to observe and evaluate the clinical value of interleukin (IL)-11 in the serum and exhaled breath condensate of patients with non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>A total of 91 patients with NSCLC and 72 healthy volunteers were included in this study. IL-11 concentration was determined by ELISA, and the relationship between IL-11 expression in serum and exhaled breath condensate specimens, and the clinicopathological characteristics of patients with NSCLC were analyzed. The relationship between serum IL-11 expression and traditional tumor markers and inflammation indicators of NSCLC was also analyzed. The correlation between serum IL-11 and exhaled breath condensate IL-11 level was determined. The receiver operating characteristic curve was used to evaluate the diagnostic value of IL-11 and carcinoembryonic antigen single and combined detection for NSCLC. The published data from online databases were used to analyze the relationship between the expression of IL-11 and the prognosis of NSCLC.</p><p><strong>Results: </strong>IL-11 concentration in serum and exhaled breath condensate specimens of patients with NSCLC were significantly increased. IL-11 expression was positively correlated with lymph node metastasis, distant metastasis, tumor node metastasis stage, and tumor differentiation degree of NSCLC. The expression of IL-11 in serum was positively correlated with that in exhaled breath condensate specimens. IL-11 expression was closely related to that of neutrophil-to-lymphocyte ratio and carcinoembryonic antigen. The combination of serum IL-11 with exhaled breath condensate IL-11 and carcinoembryonic antigen showed significantly higher diagnostic value than any one marker alone. Besides, the high IL-11 expression was closely related to the poor prognosis of NSCLC.</p><p><strong>Conclusion: </strong>IL-11 can be used as a potential diagnostic and prognostic biomarker for NSCLC.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"36 2","pages":"64-76"},"PeriodicalIF":2.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/17246008211023515","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39244285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of cluster of differentiation molecule-associated microRNAs as potential therapeutic targets for gastrointestinal cancer immunotherapy.","authors":"Hanyu Zhang,&nbsp;Mingxing Li,&nbsp;Parham Jabbarzadeh Kaboli,&nbsp;Huijiao Ji,&nbsp;Fukuan Du,&nbsp;Xu Wu,&nbsp;Yueshui Zhao,&nbsp;Jing Shen,&nbsp;Lin Wan,&nbsp;Tao Yi,&nbsp;Qinglian Wen,&nbsp;Xiang Li,&nbsp;Chi Hin Cho,&nbsp;Jing Li,&nbsp;Zhangang Xiao","doi":"10.1177/17246008211005473","DOIUrl":"https://doi.org/10.1177/17246008211005473","url":null,"abstract":"<p><strong>Background: </strong>Cluster of differentiation molecules are markers of immune cells that have been identified as a potential immunotherapeutic target for cancer treatment. MicroRNAs are small non-coding RNAs that act as tumor suppressors or oncogenes whose importance in diagnosis, prognosis, and treatment of gastric and colorectal cancers has been widely reported. However, their association with cluster of differentiation molecules in gastrointestinal cancers has not been well studied. Therefore, our study aimed to analyze the relationship between microRNAs and cluster of differentiation molecules in gastrointestinal cancers, and to identify cluster of differentiation molecule-associated microRNAs as prognostic biomarkers for gastrointestinal cancer patients.</p><p><strong>Methods: </strong>Targetscan, Starbase, DIANA microT, and miRDB were used to investigate microRNA profiles that might be correlated with cluster of differentiation molecules in gastrointestinal cancers. Moreover, The Cancer Genome Atlas data analysis was used to investigate the association between cluster of differentiation molecules and microRNA expression in patients with gastric, colon, rectal, pancreatic, and esophageal cancers. The Kaplan-Meier plotter was used to identify the association between overall survival and cluster of differentiation molecule-associated microRNA expression in gastrointestinal cancer patients.</p><p><strong>Results: </strong>miR-200a, miR-559, and miR-1236 were negatively associated with CD86, CD81, and CD160, respectively, in almost all types of gastrointestinal cancers, which were further verified in the in vitro studies by transfecting microRNA mimics in gastric cancer, colon cancer, pancreatic, and esophageal cell lines.</p><p><strong>Conclusion: </strong>Our study showed that miR-200a, miR-1236, and miR-559 are identified as cluster of differentiation-associated microRNAs in gastrointestinal cancers, providing a novel perspective to identify new therapeutic targets for cancer immunotherapy in gastrointestinal cancer patients.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"36 2","pages":"22-32"},"PeriodicalIF":2.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/17246008211005473","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25536515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel decision tree model based on chromosome imbalances in cell-free DNA and CA-125 in the differential diagnosis of ovarian cancer.","authors":"Weina Zhang,&nbsp;Yu-Min Zhang,&nbsp;Yuan Gao,&nbsp;Shengmiao Zhang,&nbsp;Weixin Chu,&nbsp;Guopeng Wei,&nbsp;Ke Li,&nbsp;Xuesong He,&nbsp;Long Chen,&nbsp;Li Guo,&nbsp;Shufang Luan,&nbsp;Ping Zhang","doi":"10.1177/1724600821992356","DOIUrl":"https://doi.org/10.1177/1724600821992356","url":null,"abstract":"<p><strong>Objective: </strong>CA-125 is widely used as biomarker of ovarian cancer. However, CA-125 suffers low accuracy. We developed a hybrid analytical model, the Ovarian Cancer Decision Tree (OCDT), employing a two-layer decision tree, which considers genetic alteration information from cell-free DNA along with CA-125 value to distinguish malignant tumors from benign tumors.</p><p><strong>Methods: </strong>We consider major copy number alterations at whole chromosome and chromosome-arm level as the main feature of our detection model. Fifty-eight patients diagnosed with malignant tumors, 66 with borderline tumors, and 10 with benign tumors were enrolled.</p><p><strong>Results: </strong>Genetic analysis revealed significant arm-level imbalances in most malignant tumors, especially in high-grade serous cancers in which 12 chromosome arms with significant aneuploidy (<i>P</i><0.01) were identified, including 7 arms with significant gains and 5 with significant losses. The area under receiver operating characteristic curve (AUC) was 0.8985 for copy number variations analysis, compared to 0.8751 of CA125. The OCDT was generated with a cancerous score (CScore) threshold of 5.18 for the first level, and a CA-125 value of 103.1 for the second level. Our most optimized OCDT model achieved an AUC of 0.975.</p><p><strong>Conclusions: </strong>The results suggested that genetic variations extracted from cfDNA can be combined with CA-125, and together improved the differential diagnosis of malignant from benign ovarian tumors. The model would aid in the pre-operative assessment of women with adnexal masses. Future clinical trials need to be conducted to further evaluate the value of CScore in clinical settings and search for the optimal threshold for malignancy detection.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"36 2","pages":"3-13"},"PeriodicalIF":2.0,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1724600821992356","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39032734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}